BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 27059291)

  • 1. Hydroxysafflor yellow A improves established monocrotaline-induced pulmonary arterial hypertension in rats.
    Han X; Zhang Y; Zhou Z; Zhang X; Long Y
    J Int Med Res; 2016 Jun; 44(3):569-84. PubMed ID: 27059291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxysafflor yellow A (HSYA) attenuates hypoxic pulmonary arterial remodelling and reverses right ventricular hypertrophy in rats.
    Li L; Dong P; Hou C; Cao F; Sun S; He F; Song Y; Li S; Bai Y; Zhu D
    J Ethnopharmacol; 2016 Jun; 186():224-233. PubMed ID: 27063983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baicalein attenuates monocrotaline-induced pulmonary arterial hypertension by inhibiting vascular remodeling in rats.
    Shi R; Wei Z; Zhu D; Fu N; Wang C; Yin S; Liang Y; Xing J; Wang X; Wang Y
    Pulm Pharmacol Ther; 2018 Feb; 48():124-135. PubMed ID: 29133079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perillyl alcohol suppresses monocrotaline-induced pulmonary arterial hypertension in rats via anti-remodeling, anti-oxidant, and anti-inflammatory effects.
    Beik A; Najafipour H; Joukar S; Rajabi S; Iranpour M; Kordestani Z
    Clin Exp Hypertens; 2021 Apr; 43(3):270-280. PubMed ID: 33322932
    [No Abstract]   [Full Text] [Related]  

  • 5. Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphate-dependent protein kinase type 1.
    Wang X; Yang Y; Yang D; Tong G; Lv S; Lin X; Chen C; Dong W
    J Vasc Surg; 2016 Nov; 64(5):1468-1477. PubMed ID: 26527422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.
    Behringer A; Trappiel M; Berghausen EM; Ten Freyhaus H; Wellnhofer E; Odenthal M; Blaschke F; Er F; Gassanov N; Rosenkranz S; Baldus S; Kappert K; Caglayan E
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):369-79. PubMed ID: 26742933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effect of hydroxysafflor yellow A on bleomycin- induced pulmonary inflammation and fibrosis in rats.
    Jin M; Wang L; Wu Y; Zang BX; Tan L
    Chin J Integr Med; 2018 Jan; 24(1):32-39. PubMed ID: 29294256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effects of hydroxysafflor yellow A on acute and chronic congestive cardiac failure mediated by reducing ET-1, NOS and oxidative stress in rats.
    He H; Yang X; Shi M; Zeng X; Yang J; Wu L; Li L
    J Pharm Pharmacol; 2008 Jan; 60(1):115-23. PubMed ID: 18088512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats.
    Porvasnik SL; Germain S; Embury J; Gannon KS; Jacques V; Murray J; Byrne BJ; Shacham S; Al-Mousily F
    J Pharmacol Exp Ther; 2010 Aug; 334(2):364-72. PubMed ID: 20430844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxy-Safflower Yellow A Mitigates Vascular Remodeling in Rat Pulmonary Arterial Hypertension.
    Ji XY; Lei CJ; Kong S; Li HF; Pan SY; Chen YJ; Zhao FR; Zhu TT
    Drug Des Devel Ther; 2024; 18():475-491. PubMed ID: 38405578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension.
    Lee JH; Park BK; Oh KS; Yi KY; Lim CJ; Seo HW; Lee BH
    Int Immunopharmacol; 2016 Nov; 40():196-202. PubMed ID: 27611861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HSYA alleviates secondary neuronal death through attenuating oxidative stress, inflammatory response, and neural apoptosis in SD rat spinal cord compression injury.
    Pei JP; Fan LH; Nan K; Li J; Dang XQ; Wang KZ
    J Neuroinflammation; 2017 May; 14(1):97. PubMed ID: 28468657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension.
    Mulvaney EP; Reid HM; Bialesova L; Bouchard A; Salvail D; Kinsella BT
    BMC Pulm Med; 2020 Apr; 20(1):85. PubMed ID: 32252727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective Effect of Hydroxysafflor Yellow A on Nephropathy by Attenuating Oxidative Stress and Inhibiting Apoptosis in Induced Type 2 Diabetes in Rat.
    Lee M; Zhao H; Liu X; Liu D; Chen J; Li Z; Chu S; Kou X; Liao S; Deng Y; Li H; Xie W
    Oxid Med Cell Longev; 2020; 2020():7805393. PubMed ID: 32256962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
    Yang PS; Kim DH; Lee YJ; Lee SE; Kang WJ; Chang HJ; Shin JS
    Respir Res; 2014 Nov; 15():148. PubMed ID: 25420924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiopulmonary protective effects of the selective FXR agonist obeticholic acid in the rat model of monocrotaline-induced pulmonary hypertension.
    Vignozzi L; Morelli A; Cellai I; Filippi S; Comeglio P; Sarchielli E; Maneschi E; Vannelli GB; Adorini L; Maggi M
    J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt B):277-292. PubMed ID: 27425465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dihydromyricetin prevents monocrotaline-induced pulmonary arterial hypertension in rats.
    Li Q; Wang J; Zhu X; Zeng Z; Wu X; Xu Y; Xie J; Yu J
    Biomed Pharmacother; 2017 Dec; 96():825-833. PubMed ID: 29078260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuregulin-1 improves right ventricular function and attenuates experimental pulmonary arterial hypertension.
    Mendes-Ferreira P; Maia-Rocha C; Adão R; Mendes MJ; Santos-Ribeiro D; Alves BS; Cerqueira RJ; Castro-Chaves P; Lourenço AP; De Keulenaer GW; Leite-Moreira AF; Brás-Silva C
    Cardiovasc Res; 2016 Jan; 109(1):44-54. PubMed ID: 26503987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxysafflor yellow A exerts antioxidant effects in a rat model of traumatic brain injury.
    Wang Y; Zhang C; Peng W; Xia Z; Gan P; Huang W; Shi Y; Fan R
    Mol Med Rep; 2016 Oct; 14(4):3690-6. PubMed ID: 27599591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxysafflor yellow A attenuates left ventricular remodeling after pressure overload-induced cardiac hypertrophy in rats.
    Wang J; Zhang Q; Mei X; Zhang X
    Pharm Biol; 2014 Jan; 52(1):31-5. PubMed ID: 24033225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.